ATE178485T1 - Transdermales arzneistoff-abgabesystem - Google Patents

Transdermales arzneistoff-abgabesystem

Info

Publication number
ATE178485T1
ATE178485T1 AT95922554T AT95922554T ATE178485T1 AT E178485 T1 ATE178485 T1 AT E178485T1 AT 95922554 T AT95922554 T AT 95922554T AT 95922554 T AT95922554 T AT 95922554T AT E178485 T1 ATE178485 T1 AT E178485T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
pct
cyclodextrin
date jan
sec
Prior art date
Application number
AT95922554T
Other languages
English (en)
Inventor
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Original Assignee
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arto Olavi Urtti, Maria Riitta Sutinen, Timo Petteri Paronen filed Critical Arto Olavi Urtti
Application granted granted Critical
Publication of ATE178485T1 publication Critical patent/ATE178485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95922554T 1994-07-08 1995-06-20 Transdermales arzneistoff-abgabesystem ATE178485T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413866A GB2290964A (en) 1994-07-08 1994-07-08 Transdermal drug delivery system

Publications (1)

Publication Number Publication Date
ATE178485T1 true ATE178485T1 (de) 1999-04-15

Family

ID=10758074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922554T ATE178485T1 (de) 1994-07-08 1995-06-20 Transdermales arzneistoff-abgabesystem

Country Status (12)

Country Link
US (1) US5817332A (de)
EP (1) EP0764020B1 (de)
JP (1) JP3734267B2 (de)
AT (1) ATE178485T1 (de)
AU (1) AU2740595A (de)
CA (1) CA2193129C (de)
DE (1) DE69508938T2 (de)
DK (1) DK0764020T3 (de)
ES (1) ES2130622T3 (de)
GB (1) GB2290964A (de)
GR (1) GR3030369T3 (de)
WO (1) WO1996001626A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0838225A3 (de) * 1996-10-25 1999-03-24 Hiji, Yasutake Wässrige Lösung eines Lokalanästheticum
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814087A1 (de) 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
AU778475B2 (en) * 1999-12-16 2004-12-09 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
JP2005518453A (ja) * 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DK1629844T4 (da) 2004-07-13 2012-05-29 Bayer Schering Pharma Oy Retarderet indgivelsessystem med kontrolleret initialudbrud
EP2540696B1 (de) * 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans-Karotinoide, deren Formulierung und Verwendung
WO2006135785A2 (en) * 2005-06-10 2006-12-21 Medical College Of Georgia Research Institute Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US20090252802A1 (en) * 2006-04-07 2009-10-08 Chang James N Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
KR101570131B1 (ko) 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 말초혈관질환 치료와 예방을 위한 용도
JP2011502125A (ja) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 小分子拡散を促進する新しい種類の治療法
EP2445339B1 (de) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Verteilungsverbessernde verbindung und ihre verwendung mit einem thrombolytikum
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
CA2830069C (en) 2011-03-20 2019-11-12 The University Of British Columbia Therapeutic agent for emphysema and copd
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (de) 2013-08-22 2020-01-08 The General Hospital Corporation Hemmer der humanen 12/15-lipoxygenase
WO2015031765A2 (en) 2013-08-29 2015-03-05 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
WO2015054059A2 (en) * 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CN105764494A (zh) 2013-10-07 2016-07-13 帝国制药美国公司 右旋美托咪啶经皮递送装置及其使用方法
TWI629061B (zh) * 2013-10-07 2018-07-11 美商帝國製藥美國股份有限公司 包含右美托嘧啶（ｄｅｘｍｅｄｅｔｏｍｉｄｉｎｅ）經皮組成物之疼痛處理用方法及組成物
EP3054930B1 (de) 2013-10-07 2020-12-02 Teikoku Pharma USA, Inc. Verfahren und zusammensetzungen zur transdermalen verabreichung einer nicht-sedierenden menge an descmedetomidin
EP3087985B1 (de) 2013-12-18 2018-10-17 Maruishi Pharmaceutical Co., Ltd. Wasserhaltiges adhäsif-pflaster
CN106455567A (zh) * 2013-12-18 2017-02-22 Gnt有限责任公司 用于治疗青光眼的组合物和方法
WO2016196664A1 (en) 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Methods and use of compounds that bind to rela of nf-kb
BR112018001441A2 (pt) 2015-07-28 2018-09-11 Vyome Biosciences Pvt Ltd antibacterianos terapêuticos e profiláticos
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
KR20240031326A (ko) 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
EP4308088A4 (de) 2021-11-08 2024-06-12 Weiyong Li Transdermales arzneimittelabgabesystem zur abgabe eines arzneimittels an einen patienten
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
EP0241806A1 (de) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Transdermale Zubereitungen mit verzögerter Freisetzung
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
WO1993007858A1 (en) * 1991-10-16 1993-04-29 Arto Olavi Urtti Peroral drug delivery system
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
AU2740595A (en) 1996-02-09
DE69508938T2 (de) 1999-09-16
GB2290964A (en) 1996-01-17
CA2193129A1 (en) 1996-01-25
EP0764020A1 (de) 1997-03-26
DK0764020T3 (da) 1999-10-18
US5817332A (en) 1998-10-06
CA2193129C (en) 2007-11-06
WO1996001626A1 (en) 1996-01-25
DE69508938D1 (de) 1999-05-12
EP0764020B1 (de) 1999-04-07
GR3030369T3 (en) 1999-09-30
JP3734267B2 (ja) 2006-01-11
JPH10502388A (ja) 1998-03-03
ES2130622T3 (es) 1999-07-01
GB9413866D0 (en) 1994-08-24

Similar Documents

Publication Publication Date Title
ATE178485T1 (de) Transdermales arzneistoff-abgabesystem
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE298259T1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
SE8703034D0 (sv) Oralt terapeutiskt system med systemisk verkan
DE69634009D1 (de) Implantierbare vorrichtung zur kontrollierten abgabe von arzneimitteln unmittelbar an einen inneren teil des körpers
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ATE228374T1 (de) Arzneiverabreichungssystem
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
DE69731882D1 (de) Transdermal verabreichtes dextromethorphan als hustenmittel
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE135203T1 (de) System zur peroralen arzneimittelabgabe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner